Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$51 Mln
Revenue (TTM)
$3 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.4
Industry P/E
--
EV/EBITDA
0.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-34.9
Face value
--
Shares outstanding
2,537,020
CFO
$-248.71 Mln
EBITDA
$-275.51 Mln
Net Profit
$-322.98 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Singular Genomics Systems Inc (OMIC)
| 3.0 | 1.6 | -7.7 | 26.1 | -54.7 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Singular Genomics Systems Inc (OMIC)
| 40.4 | -77.1 | -82.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Singular Genomics Systems Inc (OMIC)
|
20.0 | 50.8 | 2.7 | -86.3 | -3,195.0 | -61.7 | -- | 0.4 |
| 0.0 | 0.4 | 0.8 | -12.7 | -1,153.8 | -- | -- | 11.2 |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. It is involved in the developing of G4,... consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets. The company was incorporated in 2016 and is based in San Diego, California. As of February 21, 2025, Singular Genomics Systems, Inc. was taken private. Read more
Founder, CEO, President & Chairperson of the Board
Mr. Andrew Spaventa
Founder, CEO, President & Chairperson of the Board
Mr. Andrew Spaventa
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Singular Genomics Systems Inc (OMIC) is $20.01 (NASDAQ) as of 21-Feb-2025 09:30 EDT. Singular Genomics Systems Inc (OMIC) has given a return of -54.69% in the last 3 years.
Since, TTM earnings of Singular Genomics Systems Inc (OMIC) is negative, P/E ratio is not available.
The P/B ratio of Singular Genomics Systems Inc (OMIC) is 0.41 times as on 21-Feb-2025, a 90 discount to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.01
|
0.01
|
|
2022
|
-1.63
|
0.55
|
|
2021
|
-8.44
|
2.48
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Singular Genomics Systems Inc (OMIC) are Rs -- and Rs -- as of 05-Apr-2026.
Singular Genomics Systems Inc (OMIC) has a market capitalisation of $ 51 Mln as on 21-Feb-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Singular Genomics Systems Inc (OMIC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.